Cite
HARVARD Citation
Espeland, M. et al. (2021). Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, obesity & metabolism. 23 (2), pp. 569-580. [Online].